Focus & Attention (Children's)

Focus and Attention in Children: A Nutritional and Natural-Health Reference

1. Definition and Clinical Presentation

Attention-deficit/hyperactivity disorder (ADHD) is a developmental disorder marked by persistent symptoms of inattention, hyperactivity, and impulsivity. Within the natural-health context, impaired focus and attention in children is most commonly discussed in relation to the ADHD spectrum, but the term also encompasses subclinical difficulties — children who exhibit heightened inattention or hyperactivity without meeting full diagnostic criteria. In the subclinical domain, children may demonstrate heightened levels of inattention and hyperactivity either at home, school, or both, but may not meet the criteria for a formal diagnosis of ADHD. Despite this, their symptoms can still cause significant issues in social and family relationships, leaving parents with relatively few options for treatment. This broader spectrum of behavioral disorders covers a vast area of developmental dysfunction that is generally ignored due to the lack of diagnostic criteria.

ADHD is characterised by a pattern of developmentally inappropriate inattention, motor restlessness, and impulsivity that affects approximately 3–7% of school-aged children. Some estimates are higher: ADHD is a complex condition affecting up to 10% of children in the US and comprises a heterogeneous set of behavioral dysfunctions.

Based on specific symptoms, a person can be diagnosed with one of three types of ADHD: Inattentive (mostly symptoms of inattention but not hyperactivity or impulsivity), Hyperactive-Impulsive (mostly symptoms of hyperactivity and impulsivity but not inattention), and Combined (symptoms of both inattention and hyperactivity and impulsivity). ADHD symptoms must begin in childhood, before age 12. The prevalence of the three subtypes of ADHD are: primarily inattentive (20–30% of the diagnosed population), primarily hyperactive-impulsive (less than 15%), and combined subtype (50–75%).

Symptoms begin at a young age and usually include lack of attention, lack of concentration, disorganization, difficulty completing tasks, being forgetful, and losing things. These symptoms should be present before the age of 12, have lasted six months, and interfere with daily life activities in order to be labeled as "ADHD." ADHD is considered a dysfunction of executive functioning, predominantly a frontal lobe activity. Therefore, patients with ADHD show disability not only in attention and focus but also in decision making and emotional regulation. Children with ADHD can have difficulty with social interactions, can be easily frustrated, and can be impulsive.

2. Body Systems and Neurobiological Basis

2.1 Brain Structure and Neural Circuitry

Structural imaging studies show that brains of children with ADHD are significantly smaller than unaffected controls. The prefrontal cortex, basal ganglia, and cerebellum are differentially affected, and evidence indicating reduced connectivity in white matter tracts in key brain areas is emerging.

NIH researchers discovered that symptoms of ADHD are tied to atypical interactions between the brain's frontal cortex and information processing centers deep in the brain. The researchers examined more than 10,000 functional brain images of youth with ADHD and published their results in the American Journal of Psychiatry. Specifically, youth with ADHD had heightened connectivity between structures deep in the brain involved in learning, movement, reward, and emotion (caudate, putamen, and nucleus accumbens) and structures in the frontal area of the brain involved in attention and control of unwanted behaviors (superior temporal gyri, insula, inferior parietal lobe, and inferior frontal gyri).

The pattern of neuropsychological deficits found in ADHD children implicates executive functions and working memory; this pattern is similar to what has been found among adults with frontal lobe damage, which suggests that the frontal cortex or regions projecting to the frontal cortex are dysfunctional in at least some ADHD children. Neuroimaging studies implicate frontosubcortical pathways in ADHD. Notably, these pathways are rich in catecholamines, which have been implicated in ADHD by the mechanism of action of stimulants — the class of drugs that effectively treats many ADHD children.

2.2 Neurotransmitter Systems

Genetic, pharmacological, imaging, and animal models highlight the important role of dopamine dysregulation in the neurobiology of ADHD. The norepinephrine system is also involved. Physical activity is thought to alter the physiology of ADHD by increasing the levels of mainly dopamine and norepinephrine in the brain, thus affecting the same catecholaminergic system which is targeted by medication.

2.3 Electrophysiology

Since the 1930s, EEG studies have identified that a subgroup of children with ADHD tend to have an increase in theta and delta slow-wave activity, mostly in the frontal region. During inattentive or unfocused states, the slow theta waves (3.5–8.0 Hz) dominate the prefrontal and frontal cortices, as well as other midline loci of the brain. During relaxed, wakeful states, alpha waves (9.0–11 Hz) take over these areas of the brain.

2.4 Executive Function System

Neurocognitive models of ADHD have become more refined, and one particular executive process, inhibition, is now considered to be a core deficit. Current theories emphasise the central role of attentional and executive dysfunctions in children, as well as affective components involving emotional control and motivational processes.

3. Contributing and Associated Factors

3.1 Genetics

There are multiple genetic and environmental risk factors with small individual effect that act in concert to create a spectrum of neurobiological liability. A growing body of evidence supports a model in which multiple genetic and environmental factors interact during early development to create a neurobiological susceptibility to the disorder; the expression of which is mediated by alterations within different and diverse neural networks and deficits in the neuropsychological functions that these subserve.

3.2 Environmental Exposures

Specific environmental exposures that seem to have relevance to the ADHD phenotype include organic pollutants (e.g., pesticides, polychlorinated biphenyls [PCBs]) and lead. These may damage cognitive and neural systems known to be implicated in ADHD. Associations between organophosphate pesticide exposure and ADHD have been investigated cross-sectionally and prospectively using assessments of prenatal and postnatal urinary organophosphate metabolites and umbilical cord plasma levels of pesticides.

3.3 Prenatal and Perinatal Factors

Researchers are looking at differences in brain development and neurobiology among people with ADHD compared to those without the disorder. They are also studying environmental factors that might increase the risk of developing ADHD, including brain injuries, nutrition, and social environments. Premature birth and low birth weight have also been implicated: the findings at least suggest the need for heightened awareness of possible ADHD in very premature/low birth weight children.

3.4 Dietary and Nutritional Factors

Nutrition is currently considered an influencing factor, and several studies have explored the contribution of restriction and dietary supplements in ADHD treatments. Environmental factors correlated with the risk of developing ADHD include exposure to toxicants, nutrition deficiencies, events during pregnancy and birth, deprivation, stress, infection, poverty, and trauma.

3.5 Sleep

Sleep difficulties, including difficulty falling asleep, remaining asleep, and waking early, are common with ADHD. These difficulties may be perpetuated by circadian rhythm difficulties. Sleep problems are highly prevalent in children with ADHD. The relationship between sleep and ADHD symptoms appears bidirectional: for children and adolescents, enhanced cognitive functioning resulting from physical activity was most clearly seen in executive functions. Preliminary evidence suggests that participation in regular physical activity is associated with reduced severity of ADHD symptoms, the development of motor proficiency, and improved sleep problems.

4. Nutrients Studied in Relation to Children's Focus and Attention

4.1 Omega-3 Polyunsaturated Fatty Acids (EPA and DHA)

Background

Omega-3 polyunsaturated fatty acids (PUFAs) have gained attention as a potential adjunctive treatment for ADHD due to their roles in cognitive and neurobiological functions such as attention and focus, impulse control, executive function, working memory and neurotransmitter regulation, as well as brain development, mainly in the prefrontal cortex.

Observational Evidence

Several studies have demonstrated differences in omega-3 fatty acid composition in plasma and in erythrocyte membranes in patients with ADHD compared with unaffected controls. A systematic review and meta-analysis found: children and adolescents with ADHD have lower levels of DHA (seven studies, n=412) and EPA (seven studies, n=468) compared to controls.

Proposed Mechanism

Omega-3 fatty acids have anti-inflammatory properties and can alter central nervous system cell membrane fluidity and phospholipid composition. Cell membrane fluidity can alter serotonin and dopamine neurotransmission.

Clinical Evidence

A systematic review of 16 randomized controlled trials included a total of 1,514 children and young people with ADHD who were allocated to take an omega-3/6 intervention or a placebo. Of the studies identified, 13 reported favorable benefits on ADHD symptoms including improvements in hyperactivity, impulsivity, attention, visual learning, word reading, and working/short-term memory.

A separate meta-analysis (Bloch and Qawasmi, 2011, published in the Journal of the American Academy of Child and Adolescent Psychiatry) found: omega-3 fatty acid supplementation demonstrated a small but significant effect in improving ADHD symptoms. Eicosapentaenoic acid dose within supplements was significantly correlated with supplement efficacy. No evidence of publication bias or heterogeneity between trials was found. Omega-3 fatty acid supplementation, particularly with higher doses of eicosapentaenoic acid, was modestly effective in the treatment of ADHD.

A 2017 meta-analysis of seven RCTs (n=534) found: n-3 PUFAs supplementation improves ADHD clinical symptom scores (g=0.38, p<0.0001); and in three RCTs totalling n=214 randomized youth with ADHD, n-3 PUFAs supplementation improves cognitive measures associated with attention (g=1.09, p=0.001).

Evidence Strength and Limitations

The relative efficacy of omega-3 fatty acid supplementation was modest compared with currently available pharmacotherapies for ADHD such as psychostimulants, atomoxetine, or α2 agonists. However, given its relatively benign side-effect profile and evidence of modest efficacy, it may be reasonable to use omega-3 fatty supplementation to augment traditional pharmacologic interventions or for families who decline other psychopharmacologic options. The outcomes varied across studies, with some reporting significant improvements in cognition and behavior, while others found no omega-3 superiority over placebo. Overall, the evidence is consistent but modest in magnitude, and effect sizes are considerably smaller than for pharmacotherapy.

4.2 Iron

Background and Biological Role

Iron is an essential cofactor required for a number of functions, such as transport of oxygen, immune function, cellular respiration, neurotransmitter metabolism (dopamine production), and DNA synthesis. Epidemiological studies have found that iron and zinc deficiencies are common nutritional deficits worldwide, with important roles in neurologic functions (poor memory, inattentiveness, and impulsiveness), finicky appetite, and mood changes.

Scientific Evidence

There is no conclusive data to support nutrient deficiencies as a cause of ADHD. However, research does exist demonstrating that patients with ADHD have reduced levels of vitamin D, zinc, ferritin, and magnesium. There was just one randomized clinical trial with iron supplementation in non-anemic ADHD children and one article on anemic children; results showed no positive impact on non-anemic children and positive effects on anemic ADHD children.

Iron supplementation may have benefit in reducing ADHD symptoms in children with or at high risk of deficiency. Data demonstrating efficacy of iron in non-nutrient deficient ADHD populations is lacking.

Evidence Strength

Evidence is preliminary and context-dependent: supplementation appears relevant primarily in children who are iron-deficient or have low ferritin, rather than as a general intervention for all children with attention difficulties.

4.3 Zinc

Background

Zinc plays an important role for protein and DNA synthesis, in wound healing, for bone structure, and on the immune system. Altered levels of iron and zinc have been related with the aggravation and progression of ADHD.

Scientific Evidence

Findings of studies using zinc supplementation in ADHD are mostly positive. A systematic review of nine RCTs concluded: the specific role of dietary nutrients with zinc and iron still seems controversial for the treatment of ADHD, being most consistent with the evidence for zinc. Moreover, although the reviewed studies found a relationship between the use of dietary supplements containing these elements with the improvement of ADHD symptoms, neither the mono-causal role of a concrete specific nutritional deficiency among ADHD children nor the role of a concrete dietary nutrient in the management of this disorder were proven.

A Polish study found a high rate of magnesium, zinc, iron, copper, and calcium deficiencies in 116 children with ADHD. The finding of a significant difference in the Conners scale in the magnesium- and zinc-deficient cases denotes that the deficiency of these trace elements is implicated in worsening of the symptoms of the disease.

Evidence Strength

Evidence for zinc is modest to moderate and more consistent than for iron. It is stronger in populations with documented zinc deficiency. Larger, well-controlled trials are needed before definitive conclusions can be drawn.

4.4 Magnesium

Background

Magnesium is involved in hundreds of enzymatic reactions in the body, including many related to neurotransmitter synthesis and nerve signal transmission. Research shows that patients with ADHD may have reduced levels of vitamin D, zinc, ferritin, and magnesium. These nutrients have important roles in neurologic function, including involvement in neurotransmitter synthesis.

Scientific Evidence

A study of ADHD children with magnesium deficiency (n=75) found that after 6 months, an increase in magnesium contents in hair and a significant decrease in hyperactivity was achieved. However, a systematic review that examined multiple trials concluded: there was no predominant evidence about using mineral supplementation on children with ADHD.

Many symptoms of ADHD are addressed with behavioral therapy and medications; however, even with combined treatments, one-third of patients are still symptomatic. Currently there is no evidence to support supplementation as a monotherapy for the treatment of ADHD; however, supplementation may improve medication response and overall well-being, especially in those with deficiencies.

Evidence Strength

Evidence is preliminary and mixed. Some positive signals exist in deficient populations, but the broader evidence base does not support routine magnesium supplementation as a standalone intervention.

4.5 Vitamin D

Observational Evidence

Serum vitamin D concentrations in children and adolescents with ADHD were approximately 6.93 ng/mL lower than in healthy controls. Although the difference was statistically significant, it might not be of great clinical importance. Analysis of both case-control and cross-sectional studies revealed that lower vitamin D concentrations are associated with ADHD. A causal association cannot be inferred from these types of studies because the deficiency might occur as a result of lifestyle change experienced by children with ADHD.

Proposed Mechanisms

The receptor of vitamin D and related enzymes are found in the nerve cells of the substantia nigra, hippocampus, hypothalamus, and prefrontal cortex. Data show that shortage of vitamin D during the growth period of the brain leads to destructive effects on the dopaminergic system. Vitamin D plays a role in the proliferation and differentiation of brain cells (axonal growth) and increase in antioxidant capacity and hence protection against oxidative stress and adjustment of neurotrophic factors.

Intervention Evidence

The diagnosis of vitamin D deficiency was significantly greater in children with ADHD compared with the control group. Children with ADHD had significantly lower values of serum vitamin D than the control group. The group receiving vitamin D supplementation demonstrated improvement in cognitive function in the conceptual level, inattention, opposition, hyperactivity, and impulsivity domains. Vitamin D supplementation in children with ADHD may improve cognitive function.

Regarding sleep — an important modifier of attention — compared to ADHD children with vitamin D sufficiency, significantly higher sleep duration and sleep disordered breathing scores were observed in ADHD children with vitamin D insufficiency. However, there was no direct effect of vitamin D insufficiency on the type of ADHD symptoms or functional impairment.

Evidence Strength

Evidence is preliminary. Observational associations are consistent, but intervention studies are few and mostly small. Direction of causality remains uncertain. Vitamin D insufficiency may worsen associated conditions (particularly sleep disturbance) that indirectly affect attentional performance.

5. Herbal and Plant-Derived Ingredients

5.1 Bacopa monnieri (Brahmi)

Traditional Use

Bacopa monnieri is a perennial creeping herb native to wetlands of South and Southeast Asia. Bacopa monnieri is a perennial creeping herb. A special extract of Bacopa monnieri (CDRI 08) has been subjected to hundreds of scientific studies and has been shown in human randomized controlled trials to improve memory, attention, and mood. In the Ayurvedic tradition of India, Bacopa (known as Brahmi) has been used for centuries as a medhya rasayana — a class of herbs traditionally considered to enhance intellect and memory. It was prepared as whole-herb preparations or ghee infusions and used for children to support learning and cognitive development.

Scientific Evidence

Two studies reported improvements in hyperactivity and attention in children diagnosed with ADHD. Significant outcomes demonstrated small to medium effect sizes (mean d=0.42). Bacopa monnieri was well tolerated with only 2.3% of all participants reporting mild side-effects. A systematic review of herbal medicines for ADHD noted: Bacopa monnieri consistently improved inattention, hyperactivity, and memory.

A further systematic review concluded: there is a fair indication of the efficacy and safety of Bacopa monnieri from the studies evaluated for the treatment of various symptoms of ADHD.

Evidence Strength

Evidence is promising but limited. Clinical trials in paediatric ADHD populations are few, many are open-label, and most involve small samples. Standardized trial designs are essential to confirm findings. The most promising evidence comes from open-label and small RCT studies, which carry a risk of bias.

5.2 Ginkgo biloba

Traditional Use

Ginkgo biloba, one of the world's oldest tree species, has been used in traditional Chinese medicine for thousands of years. Leaves and seeds were used in various preparations to support memory, mental clarity, and cognitive function. In Chinese herbal medicine, it has traditionally been prescribed for age-related cognitive decline and conditions involving poor concentration.

Scientific Evidence

In human studies, Ginkgo biloba significantly improved the symptoms of inattention and reduced memory impairment. A systematic review of herbal products in children and adolescents found: limited evidence was found for Ginkgo biloba and pine bark extract in ADHD, suggesting that while some trials show reductions in ADHD symptoms, the body of evidence remains insufficient to make firm recommendations. One review of specific supplements noted: studies on Ginkgo biloba have shown various effects on ADHD symptoms.

Evidence Strength

Evidence is preliminary and limited. The number of well-designed RCTs specific to children is small, and results are inconsistent across trials. Ginkgo biloba extract (EGb 761) has been used in some paediatric trials, but the evidence base does not yet support a definitive efficacy conclusion.

5.3 Pycnogenol (French Maritime Pine Bark Extract, Pinus pinaster)

Traditional Use

Pycnogenol, an extract from the bark of the French maritime pine, consists of phenolic acids, catechin, taxifolin, and procyanidins. The bark of maritime pine has been used historically in European folk traditions as an astringent remedy. Standardized extraction and study of its properties as Pycnogenol® is, however, a modern development beginning in the mid-twentieth century.

Scientific Evidence

Sixty-one children were supplemented with 1 mg/kg/day Pycnogenol or placebo over a period of 4 weeks in a randomised, placebo-controlled, double-blind study. Patients were examined at the start of the trial, 1 month after treatment, and 1 month after the end of the treatment period using standard questionnaires. Results show that 1-month Pycnogenol administration caused a significant reduction of hyperactivity, improved attention and visual-motoric coordination, and concentration of children with ADHD. In the placebo group no positive effects were found. One month after termination of Pycnogenol administration, a relapse of symptoms was noted.

A subsequent trial comparing Pycnogenol® to methylphenidate (MPH) and placebo in 88 paediatric ADHD patients found: 88 paediatric ADHD patients (70% male, mean age 10.1 years) were randomised to placebo, PBE, or MPH. Teachers reported significant improvement of total and hyperactivity/impulsivity ADHD-RS scores by PBE and MPH after 10 weeks compared to placebo. MPH also improved inattention. Ten weeks of supplementation with Pycnogenol led to significant decreases in hyperactivity/impulsivity and inattention as assessed by teachers. While the improvements were not always similar to those observed with methylphenidate, the pharmaceutical was associated with five times more adverse effects than the Pycnogenol group.

Evidence Strength

Evidence is moderate for this herbal category. Multiple small-to-medium-sized RCTs exist and show consistent signals. However, the overall evidence base is still limited in sample size, and further trials with larger populations are required. The proposed mechanism involves antioxidant action: besides dopaminergic dysfunction, immune and oxidant-antioxidant imbalances appear to be involved in ADHD, offering potential for new therapeutic approaches.

5.4 Saffron (Crocus sativus)

Traditional Use

Saffron (Crocus sativus L.) has been used medicinally for over 3,000 years across Persian, Ayurvedic, and Arab traditional medicine. Traditionally, it was used as a mood-elevating and brain-supporting herb, often prepared as a decoction or added to milk preparations for calming and cognitive benefit in children and adults alike.

Scientific Evidence

In studies conducted using Crocus sativus, patients showed significant improvements in symptoms of inattention and hyperactivity/impulsivity. One randomized trial found that short-term use of saffron capsules in ADHD patients showed similar effects to methylphenidate. A systematic review found: herbal products showing clinical promise include Bacopa monnieri, Crocus sativus, Ginkgo biloba, and others in paediatric ADHD trials.

Evidence Strength

Evidence is preliminary. The number of independent RCTs specific to paediatric populations is very small, and larger confirmatory trials are needed. Findings are promising but cannot yet be considered established.

5.5 Korean Red Ginseng (Panax ginseng)

Traditional Use

Ginseng root has been used in traditional Korean and Chinese medicine for centuries as a tonic herb to improve qi (vital energy), mental clarity, and stamina. In Korean medicine specifically, red ginseng (prepared by steaming and drying) has been used for memory and concentration support in children.

Scientific Evidence

In studies conducted using Korean Red Ginseng, patients showed significant improvements in symptoms of inattention and hyperactivity/impulsivity. Others examined the efficacy of Korean red ginseng as a single treatment compared to control in ADHD trials.

Evidence Strength

Evidence is very limited. Few clinical trials have been conducted in paediatric populations, and existing studies are generally small and methodologically heterogeneous. Results are preliminary only.

6. Dietary Factors

6.1 Artificial Food Colorings (Synthetic Food Dyes)

The question of whether artificial food colorings worsen hyperactivity and attention difficulties has been studied since the 1970s. Research into the effect of food on ADHD started forty years ago when pediatric allergist Benjamin Feingold hypothesized that both artificial food additives (colorings and flavors) and foods rich in salicylates might be important etiologic agents of the hyperkinetic syndrome.

The cumulative evidence from systematic reviews and subsequent double-blind, placebo-controlled challenge studies indicates that artificial food colorants and benzoate preservatives are associated with increases in hyperactive behavior in children, irrespective of a prior ADHD diagnosis or baseline levels of hyperactivity. A meta-analysis of double-blind placebo-controlled trials found a modest but significant association between artificial food colorings and increased hyperactivity in sensitive children with hyperactive syndromes.

A 2012 meta-analysis by Nigg et al., which combined 20 studies with 794 participants, found a small effect size (SMD=0.18, 95% CI 0.08–0.29). It also found evidence of publication bias. Correcting for the bias led to a tiny effect size at the outer margin of statistical significance (SMD=0.12, 95% CI 0.01–0.23). The study authors concluded the evidence was too weak to justify action recommendations absent a strong precautionary stance, but too substantial to dismiss.

Recent systematic reviews and meta-analyses indicate associations between dye exposure and behavioral changes, with mechanisms involving oxidative stress, mitochondrial dysfunction, and disruption of dopamine and serotonin metabolism leading to neuroinflammation and impaired impulse control.

A review by FDA concluded: the effect-size of artificial food color (AFC)-free diets on ADHD was small to medium such that dietary intervention that excludes AFCs should not be advised as general ADHD treatment.

Overall evidence strength: Modest, consistent, but small in effect size. The association is replicated across multiple meta-analyses but effect sizes are small and a proportion of the signal may be attributable to publication bias. It is likely that only a subgroup of children — potentially those with genetic variants affecting metabolism of these compounds — show meaningful behavioral responses.

6.2 Dietary Patterns and Ultra-Processed Foods

A meta-analysis that assessed how ADHD was affected by dietary patterns found that diets high in refined sugar increased the risk of ADHD or hyperactivity. However, this association may be confounded by other dietary and lifestyle patterns common in children who consume high quantities of ultra-processed foods. In children with pre-existing behavioral difficulties, dietary exposures such as artificial colorants and preservatives found in ultra-processed foods may exacerbate symptoms to a clinically meaningful extent.

6.3 Sugar

Despite widespread popular belief, the scientific evidence does not support a direct effect of sugar on attention or hyperactivity. A 1995 meta-analysis by Wolraich et al., published in JAMA, analyzed 23 controlled studies and concluded that sugar does not affect the behavior or cognitive performance of children. Multiple subsequent studies have confirmed this finding. Despite widespread parental belief, systematic reviews have not found a consistent link between sugar intake and ADHD symptoms or hyperactive behavior.

6.4 The Few-Foods (Elimination) Diet

A systematic review of meta-analyses identified six that confined to double-blind placebo-controlled trials applying homogeneous diet interventions, including artificial food color (AFC) elimination, a few-foods diet (FFD), and polyunsaturated fatty acid (PUFA) supplementation. The few-foods or oligoantigenic diet — which removes most common allergenic and additive-containing foods — has shown more substantial effects in some trials than simple AFC elimination alone, but applying it is highly demanding and requires careful clinical supervision to avoid nutritional deficiencies.

7. Lifestyle Factors

7.1 Physical Activity and Exercise

Research indicates that physical activity might augment cognitive performance, modulate neurotransmitter activity, and boost self-regulation, hence mitigating fundamental ADHD symptoms. A meta-analysis of 10 RCTs found: physical activity intervention had a moderate effect in improving attention problems in school-aged children with ADHD (SMD=−0.48, 95% CI: 0.85, −0.07, p<0.05).

Physical activity is recognized to improve cognitive performance by elevating neurotransmitter levels, including dopamine and norepinephrine, which are essential for attention and executive function. Exercise-induced neuroplasticity may enhance cognitive performance by fostering the development of new brain connections and reinforcing existing ones. Cognitively engaging exercise is more effective than traditional aerobic exercise in improving attentional problems in school-age children with ADHD.

Physical activity has, compared with other non-pharmacological interventions such as behavioural therapy, neurofeedback, and cognitive training, been shown to have the largest effect on cognitive difficulties in children, adolescents, and adults with ADHD.

A further systematic review and meta-analysis found: the effect size (Hedges' g) was −0.37 (95% CI [−0.72, −0.02]), signifying a moderate yet statistically significant decrease in ADHD symptoms after physical activity interventions. This highlights the possibility of physical activity to function as an adjuvant treatment for ADHD, supplementing conventional pharmaceutical and behavioral therapies.

7.2 Sleep

Sleep difficulties, including difficulty falling asleep, remaining asleep, and waking early, are common with ADHD. The relationship between sleep quality and attentional performance in children is well established: poor sleep directly degrades executive function and attention the following day. ADHD symptoms have improved as a result of chronobiological interventions, including light therapy and long-term melatonin treatment. Findings underscore the importance of screening for vitamin D insufficiency in children with ADHD, particularly given its association with sleep disturbances, which may indirectly affect symptom severity.

7.3 Screen Time and Environmental Stimulation

While a detailed review of screen-time research is beyond the scope of this article, the broader literature on environmental factors notes that high-stimulation digital environments may interact with underlying neurobiological vulnerabilities in children prone to attention difficulties. Along with genetic factors, it is possible that environmental factors including toxins and diet may affect symptom severity.

8. Summary of Evidence by Category

• Omega-3 fatty acids (EPA/DHA): The most consistently studied nutritional intervention. Multiple meta-analyses of RCTs show a small but statistically significant, replicated effect. Effect size is modest compared to pharmacotherapy. Evidence strength: moderate.
• Zinc: Observational evidence links low zinc to ADHD symptom severity; RCTs in deficient children show mostly positive results. Effect in non-deficient populations is unproven. Evidence strength: preliminary to moderate (in deficient populations).
• Iron (ferritin): Low ferritin is associated with ADHD. Limited RCT evidence supports supplementation only in iron-deficient or anemic children. Evidence strength: preliminary and context-dependent.
• Magnesium: Observational studies suggest lower levels in ADHD children; some uncontrolled trials show benefit in deficient populations. Systematic reviews find insufficient evidence for broad recommendation. Evidence strength: preliminary and mixed.
• Vitamin D: Consistent observational association with ADHD; preliminary intervention data suggest possible benefit in deficient children, partly mediated through sleep improvement. Evidence strength: preliminary.
• Pycnogenol (Pine bark extract): Multiple small RCTs show significant improvements in attention and hyperactivity. Evidence strength: preliminary to moderate; requires replication in larger trials.
• Bacopa monnieri: Open-label and small RCT evidence suggests improvements in inattention and memory in ADHD children. Evidence strength: preliminary.
• Ginkgo biloba: A small number of trials report modest positive effects; evidence is limited and not yet sufficient for firm conclusions. Evidence strength: limited and preliminary.
• Saffron (Crocus sativus): Very preliminary; small number of trials suggest effects comparable to methylphenidate in one study, but evidence base is insufficient. Evidence strength: very preliminary.
• Artificial food colorings: Small but reproducible effect across meta-analyses; most relevant in a sensitive subgroup of children. Effect is not sufficient to recommend AFC elimination as a general treatment. Evidence strength: modest and consistent but small in effect size.
• Physical activity: Meta-analyses of RCTs show moderate, statistically significant improvements in attentional problems. Cognitively engaging exercise appears superior to standard aerobic exercise. Evidence strength: moderate and growing.
• Sugar: Multiple meta-analyses and controlled trials find no meaningful direct effect on children's behavior or attention. Evidence strength: well-studied; no meaningful effect found.

References

• Banaschewski T et al. "The neurobiological basis of ADHD." PMC / NIH, 2010.
• Keehn B et al. "Linking ADHD to the Neural Circuitry of Attention." PMC / NIH, 2017.
• Lange KW et al. "Attention Deficit Hyperactivity Disorder." StatPearls / NCBI Bookshelf, 2023.
• National Institute of Mental Health (NIMH). "ADHD: What You Need to Know."
• Faraone SV et al. "Neurobiology of attention-deficit hyperactivity disorder." PubMed, 1998.
• NIH/NIMH. "Researchers Identify Brain Connections Associated With ADHD in Youth." 2024.
• Chimiklis AL et al. "Mind–Body Therapy for Children with ADHD." PMC / NIH, 2017.
• Thapar A et al. "What causes attention deficit hyperactivity disorder?" PMC / NIH, 2013.
• Dhaliwal JS et al. "Omega-3 Polyunsaturated Fatty Acid Supplementation in Children With ADHD." PMC / NIH, 2025.
• Hawkey E, Nigg JT. "Do Omega-3/6 Fatty Acids Have a Therapeutic Role in Children and Young People with ADHD?" PubMed, 2017.
• Bloch MH, Qawasmi A. "Omega-3 fatty acid supplementation for the treatment of children with ADHD: systematic review and meta-analysis." NCBI Bookshelf / DARE, 2011.
• Chang JP et al. "Omega-3 Polyunsaturated Fatty Acids in Youths with ADHD: a Systematic Review and Meta-Analysis." PubMed, 2017.
• Villagomez A, Ramtekkar U. "Iron, Magnesium, Vitamin D, and Zinc Deficiencies in Children Presenting with Symptoms of ADHD." PMC / NIH, 2014.
• Perez-Fernandez C et al. "The Role of Iron and Zinc in the Treatment of ADHD among Children and Adolescents: A Systematic Review of Randomized Clinical Trials." Nutrients, MDPI, 2021.
• Bloch MH, Mulqueen J. "Nutritional Supplements for the Treatment of ADHD." PMC / NIH, 2014.
• Khoshbakht Y et al. "Vitamin D Status and ADHD: A Systematic Review and Meta-Analysis of Observational Studies." PMC / NIH, 2018.
• Frontiers in Psychiatry. "Vitamin D insufficiency and sleep disturbances in children with ADHD: a case-control study." 2025.
• Mohammadpour N et al. "Impact of Vitamin D Supplementation on ADHD in Children." PubMed, 2018.
• Pashazadeh Kan F et al. "Phytotherapy for ADHD: A Systematic Review and Meta-analysis." PMC / NIH, 2022.
• Trebatická J et al. "Treatment of ADHD with French maritime pine bark extract, Pycnogenol." PubMed, 2006.
• Weyns AS et al. "Clinical Investigation of French Maritime Pine Bark Extract on ADHD compared to Methylphenidate and Placebo." Journal of Functional Foods, 2022.
• Kean JD et al. "A systematic review of the Ayurvedic medicinal herb Bacopa monnieri in child and adolescent populations." ScienceDirect, 2016.
• Pelsser LM et al. "Diet and ADHD, Reviewing the Evidence: A Systematic Review of Meta-Analyses." PMC / NIH, 2017.
• PMC. "A Review of the Association of Blue Food Coloring With ADHD Symptoms in Children." PMC / NIH, 2022.
• McCann D et al. "Food additives and hyperactivity." PMC / NIH, 2008.
• PMC. "Protecting developing brains: urgent need to regulate synthetic food dyes in children's diets." PMC / NIH, 2025.
• Pediatric Research. "ADHD is associated with increased consumption of ultra-processed foods among children." Nature/Pediatric Research, 2026.
• Zuo X et al. "Effect of physical activity on attention in school-age children with ADHD: a systematic review and meta-analysis." PMC / NIH, 2023.
• PMC. "The therapeutic effects of physical activity on children with ADHD: A systematic review and meta-analysis." PMC / NIH, 2025.
• PMC. "Physical Activity and Executive Function in Children With ADHD: The Mediating Role of Sleep." PMC / NIH, 2022.
• PMC. "Vitamin D levels in children with ADHD: Association with seasonal and geographical variation, supplementation, inattention severity." PMC / NIH, 2021.